The University of Chicago Header Logo

Connection

Gini Fleming to Recombinant Fusion Proteins

This is a "connection" page, showing publications Gini Fleming has written about Recombinant Fusion Proteins.
Connection Strength

0.090
  1. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecol Oncol. 2012 Apr; 125(1):136-40.
    View in: PubMed
    Score: 0.090
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.